Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647641 · ClinicalTrials.gov registry record
The CurePSP Genetics Program
A clinical trial of Corticobasal Degeneration and Corticobasal Syndrome, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06647641 is a study of Corticobasal Degeneration and Corticobasal Syndrome that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants, below the 1,845-participant average among 7 other Corticobasal Degeneration trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06647641, a study of Corticobasal Degeneration and Corticobasal Syndrome, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.
Conditions Studied
Interventions
- OTHER Whole genome sequencing will be performed at the NIH
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06647641
The ClinicalTrials.gov registry entry for NCT06647641 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,845-participant average among 7 other Corticobasal Degeneration trials with a reported enrollment target (46% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Corticobasal Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Whole genome sequencing will be performed at the NIH is the first listed.
NCT06647641 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06647641 about?
NCT06647641 is a clinical study titled "The CurePSP Genetics Program". This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological condi...
What is the current status of trial NCT06647641?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-10-08. Estimated completion is 2030-12-31.
What conditions does trial NCT06647641 study?
This clinical trial studies the following conditions: Corticobasal Degeneration, Corticobasal Syndrome, Corticobasal Degeneration (CBD), MSA - Multiple System Atrophy, Corticobasal Syndrome(CBS).
What interventions are being tested in trial NCT06647641?
The interventions under investigation include: Whole genome sequencing will be performed at the NIH (OTHER).
Who is sponsoring clinical trial NCT06647641?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06647641 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corticobasal Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gait Analysis in Neurological Disease
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
Scrambler Therapy for Corticobasal Syndrome-Associated Pain
RECRUITING · NA
-
Modifiable Variables in Parkinsonism (MVP)
RECRUITING
-
Imaging Studies in Corticobasal Syndrome
RECRUITING
-
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.